Intellia Therapeutics Inc

-1.18 (-0.90%)
Products, Strategic Combinations

Intellia Therapeutics And Sparingvision Announce Strategic Collaboration To Develop Novel Ocular Therapies Using Crispr/Cas9 Technology

Published: 10/13/2021 11:18 GMT
Intellia Therapeutics Inc (NTLA) - Intellia Therapeutics and Sparingvision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using Crispr/cas9 Technology.
Intellia - Will Grant Sparingvision Exclusive Rights to in Vivo Crispr/cas9 Technology for Development of Ocular Therapies Directed to Three Targets.
Intellia - to Receive Equity Stake in Sparingvision, to Have Option to Obtain Exclusive U.S. Commercialization Rights for Ocular Therapies for 2 Targets.